Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
AMPA
antiepileptic drug
antitumor
glioblastoma
perampanel
Journal
Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
20
07
2022
accepted:
03
10
2022
entrez:
25
10
2022
pubmed:
26
10
2022
medline:
27
10
2022
Statut:
ppublish
Résumé
Patients with glioblastoma frequently suffer epileptic seizures and often require anticonvulsant therapy during the treatment course. The present study investigated four common antiepileptic drugs, perampanel, carbamazepine (CBZ), sodium valproate (VPA) and levetiracetam (LEV), which are expected to have antitumor effects, and determined the most beneficial drug for the treatment of malignant glioma by comparing antitumor effects such as inhibition of cell proliferation and suppression of migration and invasion (using Transwell assays). The inhibition of cell growth was investigated using six malignant glioma cell lines (A‑172, AM‑38, T98G, U‑138MG, U‑251MG and YH‑13). Significant inhibition of cell proliferation was observed in all six cell lines treated with perampanel, three cell lines treated with CBZ, four cell lines treated with VPA and two cell lines treated with LEV at the therapeutic blood concentration levels for the drugs to be used as antiepileptics. Further antitumor effects in combination with temozolomide were investigated using T98G and U‑251MG cell lines, and were confirmed in both cell lines with perampanel and in T98G cells with LEV, but not observed with CBZ and VPA. Cell migration was significantly suppressed in both T98G and U‑251MG cell lines with perampanel, but not with CBZ, VPA or LEV. To investigate the mechanisms by which perampanel suppresses the migration of malignant glioma cells, the expression of mRNA related to epithelial‑mesenchymal transition following perampanel treatment was analyzed using reverse transcription‑quantitative PCR in the T98G and U‑251MG cell lines. The expression of
Identifiants
pubmed: 36281939
doi: 10.3892/or.2022.8431
pii: 216
pmc: PMC9641707
doi:
pii:
Substances chimiques
Anticonvulsants
0
Levetiracetam
44YRR34555
perampanel
H821664NPK
Matrix Metalloproteinase 2
EC 3.4.24.24
Valproic Acid
614OI1Z5WI
Temozolomide
YF1K15M17Y
Carbamazepine
33CM23913M
Cadherins
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Mol Sci. 2019 Apr 11;20(7):
pubmed: 30978987
Cancers (Basel). 2021 Jul 27;13(15):
pubmed: 34359673
Anticancer Res. 2018 Jul;38(7):4361-4366
pubmed: 29970574
FASEB J. 2014 Mar;28(3):1317-30
pubmed: 24327606
PLoS One. 2019 Feb 4;14(2):e0211644
pubmed: 30716120
J Oncol. 2010;2010:430142
pubmed: 20652056
Neurooncol Pract. 2021 May 28;8(5):501-517
pubmed: 34589231
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):504-9
pubmed: 23523186
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Int J Mol Sci. 2020 Mar 12;21(6):
pubmed: 32178267
Cell Physiol Biochem. 2016;39(6):2173-2185
pubmed: 27802437
Cancer Cell Int. 2018 Sep 10;18:136
pubmed: 30214378
Epilepsy Behav. 2011 Aug;21(4):331-41
pubmed: 21763207
Neurology. 2012 Aug 7;79(6):589-96
pubmed: 22843280
J Clin Oncol. 2009 Sep 1;27(25):4155-61
pubmed: 19636006
Cancer Treat Rev. 2018 Jul;68:145-154
pubmed: 30032756
J Pers Med. 2021 May 10;11(5):
pubmed: 34068749
Oncogene. 2003 Nov 13;22(51):8233-45
pubmed: 14614447
Mutat Res. 2004 Oct 4;554(1-2):23-32
pubmed: 15450401
Neurol Med Chir (Tokyo). 2017;57(Suppl 1):9-102
pubmed: 28420810
Nat Rev Neurosci. 2014 Jul;15(7):455-65
pubmed: 24946761
Int J Oncol. 2010 Jun;36(6):1367-77
pubmed: 20428759
Clin Cancer Res. 2004 Jun 1;10(11):3728-36
pubmed: 15173079
J Neurooncol. 2016 Sep;129(3):461-469
pubmed: 27377653
Neuro Oncol. 2009 Jun;11(3):260-73
pubmed: 18957620
Front Oncol. 2021 Sep 10;11:687362
pubmed: 34568018
Mol Oncol. 2015 Oct;9(8):1612-25
pubmed: 26022108
Neurology. 2011 Sep 20;77(12):1156-64
pubmed: 21880994
Int J Clin Exp Pathol. 2020 Oct 01;13(10):2637-2647
pubmed: 33165445
Cancer. 2010 Apr 1;116(7):1776-82
pubmed: 20143438
J Clin Oncol. 2016 Mar 1;34(7):731-9
pubmed: 26786929
Oncol Lett. 2022 Oct 07;24(6):421
pubmed: 36284648